We have relied on PSA for decades, but what’s next in precision screening for prostate cancer? In this episode of BackTable Urology, Dr. Jason Hafron from the Michigan Institute of Urology joins host Dr. Ruchika Talwar to discuss the evolving role of biomarkers and artificial intelligence in prostate cancer screening.
---
This podcast is supported by:
Cleveland Diagnostics
https://www.isopsa.com/
---
SYNPOSIS
Together, Dr. Hafron and Dr. Talwar examine the ongoing challenges of PSA testing and the promise of next-generation blood-based biomarkers, including 4Kscore and IsoPSA tests. They explore how these advancements are reshaping detection, diagnosis, and risk stratification. The episode also highlights how these tools may improve active surveillance protocols, reduce unnecessary biopsies, and better personalize prostate cancer management for better outcomes.
---
TIMESTAMPS
0:00 - Introduction
2:23 - Limitations of PSA
10:21 - Limitations of MRI
18:08 - Overview of Biomarkers (IsoPSA, 4K, PHI, SelectMDx, MIPS, ExoDx)
26:30 - Artificial Intelligence
---
RESOURCES
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial
https://jamanetwork.com/journals/jama/fullarticle/2817323
Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA
https://pubmed.ncbi.nlm.nih.gov/36965817/
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study
https://pubmed.ncbi.nlm.nih.gov/35840465/
